PhRMA

APRIL 28, 2025

As the United States confronts a resurgence of measles – a disease that was declared eliminated from the United States in 2000 through immunization – it’s a timely reminder of why vaccines remain one of the most powerful tools for preventing dangerous disease, protecting public health and reducing burden on the health care system.

Immunization 146

Immunization Vaccines 146

PhRMA

APRIL 28, 2025

April marks Medicaid Awareness Month –– a time to recognize the profound impact of the Medicaid program on the more than 80 million low-income Americans whom it serves, as well as the vital role the biopharmaceutical industry plays in ensuring these patients can access affordable medicines and treatments. Established in 1965 as part of President Lyndon B.

Insurance 146

Insurance 146

PhRMA

APRIL 25, 2025

Every April 26th, World Intellectual Property (IP) Day marks a time to celebrate the creativity and innovation that fuel our economy. In 2025, the spotlight is on music—a universal language that connects people, culture and moments. But what if you couldn’t hear it? What if the joy of music was locked away, not by choice, but by biology?

146

146

PhRMA

APRIL 10, 2025

These days, the same big health care conglomerate could own your PBM, insurer, pharmacy and even your doctor’s office. Middlemen now control what medicines you can get, what you pay at the pharmacy counter, what pharmacy you can you use and what hoops you must jump through to get the medicine your doctor prescribed.

Insurance 138

Insurance 138

PhRMA

APRIL 7, 2025

For more than four decades since the passage of the Hatch-Waxman Act, the U.S. generic drug market has provided patients with low-cost alternatives to brand-name medicines, saving the health care system billions while preserving incentives for biopharmaceutical innovation. Today, low-cost generics account for nine out of every 10 prescriptions dispensed in the United States and come with an average copay of about six dollars.

130

130

PhRMA

MARCH 28, 2025

Intellectual property (IP) protections are the foundation of U.S. global leadership in biopharmaceutical innovation. Patents and other IP protections over the past 25 years have fueled the delivery of over 750 new medicines for debilitating and devastating illnesses, such as cancer, heart disease and many rare diseases, by giving innovators the legal protection and confidence they need to take on the significant costs and risks associated with drug development.

FDA 198

FDA 198

PhRMA

MARCH 24, 2025

A new report by the Wall Street Journal reveals abuse of the 340B hospital markup program is getting worse as hospitals and middlemen find new ways to profit off the program.

Hospitals 245

Hospitals 245

PhRMA

MARCH 18, 2025

The United States leads the world in the research, development and manufacturing of innovative medicines. But the Inflation Reduction Act’s (IRA) “pill penalty” puts this leadership at risk by discouraging the development of treatments that often come in pill form like a tablet or capsule, also known as small molecule medicines. Under the IRA, these treatments can be price set years before other medicines, signaling to researchers that developing them is not worth the risk.

212

212

PhRMA

MARCH 17, 2025

Half of every dollar spent on medicines goes to entities that don’t make medicine—like pharmacy benefit managers (PBMs) and insurers who are aggressively consolidating their control over health care and hospitals, clinics and for-profit pharmacies in the 340B markup program. As entities in the supply chain that don’t make medicine are increasingly using medicines to subsidize other parts of their business, patients and employers face increasing costs and barriers to accessing c

Insurance 266

Insurance Hospitals 266

PhRMA

MARCH 16, 2025

We live in a world where technology is playing an increasingly significant role in our daily lives. In the biopharmaceutical industry, using artificial intelligence (AI) as a tool can help improve efficiency, discover new cures and treatments and enhance clinical trials. The American biopharmaceutical sector is built on a strong foundation of intellectual property protections and a flexible regulatory framework, both of which foster life-saving innovation in the United States.

146

146

PhRMA

MARCH 12, 2025

Health care practitioners (HCPs), and patients too, are sounding the alarm on unnecessary barriers in the system that can negatively impact patients’ access to quality care according to a new survey of HCPs and patients. Specifically, HCPs raised concerns over how pharmacy benefit managers (PBMs) and insurers inappropriately use utilization management tools, like prior authorization, to deny or delay care, ultimately harming the patient and impacting patient access to care.

Patient Care 301

Patient Care Insurance 301

PhRMA

MARCH 12, 2025

President Trump has made it clear that his administration is focused on supporting American workers and manufacturers, while tackling unfair and non-reciprocal trade practices by foreign governments. PhRMA and its members share these goals. To help inform the administration’s America First Trade Policy, PhRMA submitted comments to the U.S. Trade Representative (USTR) highlighting policies abroad that harm American biopharmaceutical innovation and leadership.

100

100

PhRMA

MARCH 10, 2025

Measles was declared eliminated in the United States in 2000, thanks to widespread vaccination with the MMR vaccine. Unfortunately, in recent weeks, there has been an alarming increase in measles cases across the country – from Texas and New Mexico to New York and Rhode Island and the first reported death in a decade.

Vaccines 146

Vaccines 146

PhRMA

MARCH 6, 2025

Lawmakers on both sides of the aisle are renewing a multi-year effort to crack down on drug middlemen, known as pharmacy benefit managers (PBMs). These middlemen control what patients pay at the pharmacy counter, where they can get their medicine, what medicines they can get and what hoops they must jump through. The effort in Congress reflects mounting pressure to hold PBMs accountable and help lower patients’ out-of-pocket costs.

179

179

PhRMA

MARCH 5, 2025

It’s well understood that without clinical trials there wouldn’t be all the groundbreaking innovative, life-saving drugs that patients rely on, but less understood is their significant economic impact across the United States. New research by TEConomy Partners, in concert with PhRMA, quantifies the impact of clinical trials across all 50 states, Puerto Rico and the District of Columbia.

170

170

PhRMA

MARCH 4, 2025

A tranche of recent reports reveal that the 340B hospital markup program is costing states and the federal government hundreds of millions of dollars in lost tax revenue.

Hospitals 136

Hospitals 136

PhRMA

FEBRUARY 27, 2025

Today, we join patients and their loved ones from across the country and around the world in observance of Rare Disease Day. No matter how many patients may be impacted, each disease is far from rare for those who live with it every day. That’s why America’s biopharmaceutical research companies are working around the clock to develop new treatments that can provide hope and relief for those living with rare diseases.

179

179

PhRMA

FEBRUARY 20, 2025

This week, PhRMA released a new policy agenda with key facts and figures outlining America’s challenge for continued leadership in biopharmaceutical innovation and PhRMA’s proactive solutions that underpin our advocacy. Our inefficient system costs Americans more than necessary and gets in the way of our ability to prioritize keeping people healthy.

130

130

PhRMA

FEBRUARY 20, 2025

The innovation that happens every day in America’s biopharmaceutical companies prevents disease, transforms lives and creates a healthier America. While we know there are still serious illnesses that remain to be conquered, the progress we’ve made in the past 25 years has changed the lives of countless patients and their families.

112

112

PhRMA

FEBRUARY 19, 2025

I first joined the health care industry in the early 2000s. At that time, the Human Genome Project had yet to be completed. Concepts like immunotherapy, gene therapy and CAR-T were barely an idea. And there were few treatments for diseases like Hepatitis C, melanoma and cystic fibrosis.

100

100

PhRMA

FEBRUARY 19, 2025

Earlier this year, the American Cancer Society (ACS) released its annual report on cancer facts and trends – Cancer Statistics 2025. Notably, this new report found that the cancer mortality rate declined in the U.S. by an astounding 34% since peaking in 1991, averting 4.5 million deaths.

203

203

PhRMA

FEBRUARY 19, 2025

It’s well understood that without clinical trials there wouldn’t be all of the groundbreaking innovative, life-saving drugs that patients rely on, but less understood is their significant economic impact across the United States. New research by TEConomy Partners, in concert with PhRMA, quantifies the impact of clinical trials across all 50 states, Puerto Rico and the District of Columbia.

130

130

PhRMA

JANUARY 7, 2025

Half of every dollar spent on brand medicines goes to entities that play no role in the research, development, or manufacturing of those medicines, according to a new analysis by Berkeley Research Group (BRG).

100

100

PhRMA

JANUARY 10, 2025

Ahead of next week’s J.P. Morgan Healthcare Conference, several PhRMA board members spoke with investors during a virtual conversation about what the new Congress and administration should focus on as they set their 2025 health care agenda.

130

130

PhRMA

JANUARY 13, 2025

The three largest Pharmacy Benefit Managers (PBMs) continue to abuse the health care system, significantly marking up a wide range of lifesaving medicines according to a new report from the Federal Trade Commission (FTC).

100

100

PhRMA

JANUARY 14, 2025

A ground-breaking New York Times investigation reveals how a for-profit federal contractor helps hospitals abuse the 340B program to charge huge markups on medicines. 340B has become a tool for profit, benefiting large hospital systems and private corporations far more than the patients it was designed to serve.

Hospitals 100

Hospitals 100

PhRMA

JANUARY 15, 2025

This year at J.P. Morgan Healthcare Conference was one to remember.

130

130

PhRMA

JANUARY 16, 2025

Today, the Centers for Medicare and Medicaid Services (CMS) announced the next list of medicines that will be subject to government price setting under the Inflation Reduction Act (IRA). Out of the selected medicines, more than half are being targeted because of the pill penalty, sending a clear message to innovators that investments into small molecule medicines aren’t worth it despite their value to patients.

Labelling 130

Labelling 130

PhRMA

JANUARY 22, 2025

Making the best decision about which medicines to take should be a decision between patients and their doctors, not unelected bureaucrats. Price-setting boards, such as the prescription drug affordability board (PDAB) being proposed in Virginia, ignore this principle and threaten access to life-saving medicines.

100

100

PhRMA

JANUARY 24, 2025

It has been widely acknowledged that long patent examination delays cripple innovation, hinder economies, impede job creation and frustrate the launch of new products. Increased patent review times cost the global economy $10 billion annually, and are particularly harmful for small start-up firms. Every year of delay reduces the start-up’s employment growth by 21% and sales growth by 28% over the five years following the approval of the patent application.

130

130

PhRMA

FEBRUARY 3, 2025

Every day, biopharmaceutical researchers in our industry are focused on developing the medicines that patients need to prevent and treat disease. This means taking a comprehensive approach to health care, with a focus on prevention, screening and early intervention, health and wellness and building on our scientific knowledge to develop the next generation of treatments and cures.

100

100

PhRMA

FEBRUARY 5, 2025

One of the largest compounders in the U.S., Hims & Hers, is spending millions of dollars to run a misleading Super Bowl ad that misrepresents their unapproved GLP-1 medicines.

Compounding 100

Compounding 100

PhRMA

FEBRUARY 11, 2025

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view.

184

184

PhRMA

FEBRUARY 12, 2025

Policies to contain health care costs by restricting access to medicines always come with the promise of making health care more affordable and reducing government spending. But what if they’re actually doing the opposite? A new study published in JAMA on Medicaid prescription denials exposes a harsh reality: denying access to medications doesn’t save Medicaid money, it’s shifting costs in a way that hurts both patients and taxpayers.

146

146

PhRMA

FEBRUARY 12, 2025

A new report explains the flow of dollars through the pharmaceutical supply chain for commercially insured patients taking retail medicines and details how transactions between stakeholders affect patient costs at the pharmacy counter. The report also highlights how the 340B hospital markup program and increased consolidation and vertical integration among supply chain entities raises the cost of medicines for patients and employers.

Insurance 112

Insurance Hospitals 112

PhRMA

FEBRUARY 13, 2025

PhRMA recently submitted comments in response to the Centers for Medicare & Medicaid Services (CMS) proposed rule which would extend coverage of anti-obesity medicines (AOMs) in Medicare Part D and state Medicaid plans. Currently, AOMs are excluded from Medicare Part D coverage and optional in state Medicaid programs, when used specifically for the treatment of obesity, because they’re labeled as “agents used for weight loss.

Labelling 130

Labelling 130

PhRMA

JULY 20, 2023

Most insured Americans believe insurance should provide affordable access to health care (93%), but only a third (34%) say it does, according to the fourth installment of the Patient Experience Survey (PES). The survey — based on interviews with 5,000 Americans — explores this disconnect, detailing the challenges insured Americans face affording care and how practices by health insurers and middlemen put patient lifelines to access at risk.

Insurance 186

Insurance 186